NIDA Virtual Meeting: Enhancing Health Disparities Research Related to Substance Use and Addiction - Feb. 16 & 17 |
SHARE ISSUE ON |
|
|
 Sponsored by the Research Gaps and Opportunities Workgroup of the NIDA Racial Equity Initiative, this two-day virtual meeting will discuss research gaps on racial inequities in substance use and addiction and to inform NIDA’s commitment to this area by identifying short- and long-term plans for enhancing the research portfolio.
Discussion will center on research in areas where there are known racial/ethnic inequities; and where research has the greatest potential to reduce those disparities. These include, but are not limited to:
- persistent health disparities related to substance use, addiction, and related outcomes;
- a lack of attention to research questions most salient to underrepresented communities; and
- existing system bias in the scientific enterprise.
The overarching goal of the Research Gaps and Opportunities Workgroup is to engage the scientific community in identifying research priorities that can inform NIDA programs/funding opportunities and ultimately reduce health disparities and improve outcomes
February 16, 1:00-5:00pm ET: Social Determinants of Health
February 17, 1:0-4:30pm ET: Harnessing Basic Science to Understand Racial Disparities and the Impact of Racism
Find the full agenda here | Register here!
|
CTN Trial Progress
 Randomizations for Active Studies as of the February 8 trial Progress Report.
CTN-0060-A-1 - Enrolled 202
CTN-0069 - Enrolled 757
CTN-0079-A-1 - Enrolled 4
CTN-0080 - Enrolled 33
CTN-0082 - Enrolled 162
CTN-0099 - Enrolled 190
CTN-0099-A-1 - Enrolled 60
|
· · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · ·
· · · · · · · · · · · · · · · · · · · · · · ·
CTN Summary Reports for Active Protocols
 The CTN Summary Reports have been updated on the DSC CTN website and can be accessed here. For all active protocols (CTN-0060-A1, CTN-0069, CTN-0079-A1, CTN-0080, CTN-0082, CTN-0099A, CTN-0099 RCT), the Trial Progress Reports include Availability of Primary Outcome, Data Quality: Missing forms, Randomization by Month, Treatment Exposure, Flags and Triggers, as well as Participant Age, Gender, Ethnicity and Race Breakdown reports by protocol in the Inclusion Enrollment Report section. In addition, the updated Consolidated Reports include all of the aforementioned reports for all active protocols.
· · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · ·
· · · · · · · · · · · · · · · · · · · · · · ·
News from the Nodes
Big South/West
The Big South/West Node is proud to announce the publication of the primary outcome paper for the CTN-0068 ADAPT-2 study in the New England Journal of Medicine, Bupropion and Naltrexone in Methamphetamine Use Disorder, which was publicized on NPR, Reuters Health and other media across the country.
Many, many thanks to everyone who made this study possible. It is gratifying to know lives are changing for the better: one participant reported they have been taking bupropion/naltrexone since completing the study and have not used methamphetamine in over a year; another reported they were prescribed bupropion/naltrexone for methamphetamine use after the NEJM paper was published.
We are continuing to disseminate these seminal findings to the scientific community as well as working on implementation strategies with health care providers.
Health Systems
The PROUD Trial (CTN-0074) Protocol Paper has been published in Addiction Science & Clinical Practice (Campbell CI et al. PRimary Care Opioid Use Disorders treatment (PROUD) trial protocol: A pragmatic, cluster-randomized implementation trial in primary care for opioid use disorder treatment).
The 1-year extension of the intervention ends 2/28/2021 and the Final Study Report for the main trial is expected to be complete in July. We also extend a HUGE thank you to our Nurse Care Managers (NCMs)! As we near the end of the trial, we’d like to publicly recognize the PROUD NCMs for their fantastic patient care and advocacy throughout the trial and especially during the difficult time of the pandemic. The NCMs have done tremendous work starting new patients and retaining patients in care, adapting care to a virtual environment, and developing patient care plans.
The HSN will lead a COVID supplement (CTN-0117), The Impact of COVID-19 Pandemic on Substance Use Treatment Services, which will examine the major shift to virtual treatment for drug use disorders during the pandemic in a large, diverse health care system, specifically exploring potential disparities in accessing treatment using observational, electronic health record data. |
Pacific Northwest
 The Pacific Northwest Node would like to offer its huge congratulations to Andrew Saxon, MD, who is one of 6 recipients of the 2021 Nyswander/Dole "Marie" Award.
Named after Vincent Dole, MD, and Marie Nyswander, MD who founded methadone maintenance treatment in the 1960s, the award is the preeminent recognition in the field of opioid use disorder treatment. Recipients are nominated by their peers, with a committee then selecting just a handful of national honorees.
An awards program to honor all six will be held virtually on April 13, 2021 as part of AATOD's annual conference.
Congratulations and thank you for all your work on behalf of those with opioid use disorder, Dr. Saxon!
Western States
Congratulations to Keith Humphreys!
The Western States Node would like to congratulate MPI Keith Humphreys for his recent appointment as Deputy Editor-in-Chief of Addiction, the most widely cited and internationally read journal in the field.
This is an honor and tribute to Keith’s leadership in international research on alcohol and drug use disorders.
WSN Briefing on Neuroscience, Prevention, and Treatment of Addiction
WSN CTN Members Keith Humphreys, Todd Korthuis, Bonnie Halpern-Felsher and Chelsea Shover presented a briefing on the neuroscience, prevention, and treatment of addiction to the California State Assembly. They placed special attention on methamphetamine and fentanyl because of their increasing impact in California. The session was hosted by Health Committee Chair Dr. Jim Wood and Minority Leader Marie Waldron and was attended by over 40 legislative staffers. |
· · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · ·
· · · · · · · · · · · · · · · · · · · · · · ·
Virtual CTN Workshop: Reducing Disparities in SUD Treatment Among African Americans
March 3-4, 2021, 1:00pm - 5:00pm (ET)
Prior research found that African Americans (AAs): a) enter treatment later in the course of their addiction trajectory, b) are more likely to drop out of treatment, and c) have poorer treatment outcomes than non-Hispanic whites.
This workshop, organized by the CTN Minority Interest Group, will provide a) an overview of SUD treatments and outcomes for AAs, b) existing treatment research that might represent opportunities for addressing treatment disparities, c) ongoing efforts in delivering SUD treatment, including digital technologies, in Black communities, and d) effective targets for adaptations and/or implementation research that could improve SUD treatment outcomes for AAs.
The objective of this workshop is to identify potential studies that could be conducted in the CTN.
Register here!
· · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · ·
· · · · · · · · · · · · · · · · · · · · · · ·
New in the CTN Dissemination Library
Bupropion and naltrexone in methamphetamine use disorder. Trivedi MH, et al. New England Journal of Medicine 2021;384:140-153. CTN-0068 primary outcomes!
Primary Care Opioid Use Disorders Treatment (PROUD) Trial protocol: A pragmatic, cluster-randomized implementation trial in primary care for opioid use disorder treatment. Campbell CI, et al. Addiction Science & Clinical Practice 2021;16(9).
Core outcomes set for research on the treatment of opioid use disorder (COS-OUD): The National Institute of Drug Abuse Clinical Trials Network protocol for an e-Delphi consensus study. Karnik NS, et al. Addiction Science & Clinical Practice 2021;22:102.
An alternative analysis of illicit opioid use during treatment in a randomized trial of extended-release naltrexone versus buprenorphine-naloxone: A per-protocol and completers analysis. Mitchell MM, et al. Drug and Alcohol Dependence 2021;219:108422
· · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · ·
   
|
